Scarica l'app Stockscreener
1.98
2.94%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.04
Aprire:
$2.07
Volume 24 ore:
11.20M
Relative Volume:
0.88
Capitalizzazione di mercato:
$794.76M
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.1856
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
-11.61%
1M Prestazione:
+3.66%
6M Prestazione:
-73.17%
1 anno Prestazione:
-75.16%
Intervallo 1D:
$1.97
$2.088
Intervallo di 1 settimana:
$1.95
$2.22
Portata 52W:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.98 | 794.76M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesIOVA - FinancialContent
The Gross Law Firm Notifies Shareholders of Iovance Biotherapeutics, Inc. (IOVA) of a Class ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - FinancialContent
Wealth Enhancement Advisory Services LLC Lowers Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks And Legal PressureHagens Berman - ACCESS Newswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK - Bluefield Daily Telegraph
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER - GlobeNewswire
Iovance Biotherapeutics CFO Jean-Marc Bellemin to Depart - MarketScreener
ROSEN, A LEADING LAW FIRM, Encourages Iovance - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc.IOVA - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was - GlobeNewswire
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsELV - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action - ACCESS Newswire
Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class ActionIOVA - PR Newswire
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance ... - Eagle-Tribune
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders - GlobeNewswire Inc.
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline - ACCESS Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationIOVA - The Victoria Advocate
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - StreetInsider
Iovance: Amtagvi's Rocky Launch And Mounting Concerns Lead To A 'Sell' Rating - Seeking Alpha
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA) - GlobeNewswire
iovance cfo resigns to pursue new opportunities By Investing.com - Investing.com India
iovance cfo resigns to pursue new opportunities - Investing.com
Iovance Biotherapeutics IncJean-Marc Bellemin To Resign As CFO - marketscreener.com
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid promise - Investing.com India
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact Levi & ... - Bluefield Daily Telegraph
Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire
IOVA CLASS ACTION: Invest in Iovance Biotherapeutics, Inc.? - GlobeNewswire
Levi & Korsinsky Urges Iovance Biotherapeutics, Inc. (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025 - ACCESS Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - GlobeNewswire
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor LawsuitHagens Berman - ACCESS Newswire
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross ... - Bluefield Daily Telegraph
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Victoria Advocate
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER - GlobeNewswire
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
| Vogt Frederick G | Interim CEO & General Counsel |
May 14 '25 |
Buy |
1.69 |
25,000 |
42,250 |
374,646 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 14 '25 |
Option Exercise |
0.00 |
8,334 |
0 |
203,761 |
| Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
1.86%
1.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):